Cigalah Group
- Company typePrivate
- Founded1986
- HeadquartersJeddah, Saudi Arabia
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Cigalah Group firmographics
Firmographics- Name
- Cigalah Group
- Legal name
- Cigalah Group
- Website
- https://cigalah.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Where Cigalah Group is headquartered
LocationHeadquarters
- HQ city
- Jeddah
- HQ country
- Saudi Arabia
- HQ region
- Middle East
Offices8 records
Markets served
Cigalah Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Distribution: Distribution of pharmaceutical products from international partners to wholesale, retail, hospitals, health centers, and institutions across Saudi Arabia and GCC markets.
- Consumer Products Distribution: Importation, warehousing, manufacturing support, and distribution of consumer goods across 10 Distribution Hubs, serving 16,000+ outlets with own private label products in addition to international brands.
- Food Manufacturing and Export: Manufacturing and export of snack foods, cereals, and oats through Zawaq Foods facility. Production for international principals/brands plus own brands, exporting to GCC, Middle Eastern and North African markets.
- Technology Transfer and Licensing: $208.5 million deal with Astrogen for technology transfer of autism treatment AST-001 across 16 MENA countries, including supply payments and double-digit royalties on future sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B distribution services for pharmaceutical and consumer product partners |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Cigalah Group product offering
Product offeringCore offering
Cigalah Group is a Saudi Arabian sales, distribution and marketing conglomerate that distributes pharmaceutical, healthcare, consumer goods, and bio-medical products from international principals to wholesale, retail, hospital and institutional channels across the Kingdom and GCC. It operates 10 consumer products distribution hubs and 5 healthcare/pharmaceutical distribution hubs, supported by a fleet of cash vans, a medical sales force, and 36,100 sqm of GDP-compliant temperature-controlled warehousing.
Product overview
Cigalah Group is a diversified distribution and trading conglomerate operating primarily in Saudi Arabia with over 100 years of history. The company operates through six main sectors: Healthcare Sector (pharmaceutical and healthcare product distribution serving 8,000+ pharmacies), Consumer Products Sector (consumer goods distribution with 10 distribution hubs), Business Development Sector (strategic planning and market development), Bio-Medical Sector (biomedical equipment distribution), Al Saf Sector and Al-Qantarah Sector (specialized subsidiaries). Key subsidiaries include Zawaq Foods (ISO 2200/JAS-ANZ accredited snack and cereal manufacturing) and Al-Tawun Chemicals (chemical logistics). Supporting services include pharmacovigilance, quality assurance compliant with SFDA GDP and ISO 9001/2015, compliance programs, and training academy. The group has over 5,000 employees and maintains partnerships with major pharmaceutical and consumer goods companies including Julphar, Allergan, Boehringer Ingelheim, Janssen, and over 40 other international brands.
Differentiator
Problem solved
Functional benefit
Brands
- Zawaq Foods: Snack foods and cereals manufacturer established in 1994, producing potato chips, corn snacks, filled biscuits, and cereal products.
- SAF Sector
- Al-Qantarah Sector
- Cigalah Surgical Packs Factory
- Al-Tawun Chemicals
- Alpha Pharma
Companies that use Cigalah Group
Customer profileNamed customers3 records
Ideal customer profiles4 records
Cigalah Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cigalah Group partnerships and signals
Strategic signalPartnerships
27 partnerships are on record, tiered core, flagship and minor.
- AumetcoreHealthcare-focused backer and investor in Aumet's $12 million Series A funding round led by Emkan Capital. Aumet operates an AI-first procurement operating system for healthcare providers and pharmacies across Jordan, Egypt, and Saudi Arabia.
- Astrogenflagship$208.5 million exclusive agreement with Cigalah Medpharm Trading LLC for technology transfer and commercialization of autism treatment candidate AST-001 across 16 MENA countries. Includes $131 million for supply, $77.5 million upon regulatory approval, plus double-digit royalties on future sales.
- Aug PharmacoreStrategic partnership between Aug Pharma and Cigalah Egypt (affiliate of Cigalah Saudi Arabia) to boost operations in Egypt and MENA countries including Saudi Arabia and Gulf region.
- Boehringer IngelheimcoreLong-established partnership with Boehringer Ingelheim for innovative therapies in cardiovascular, respiratory diseases and diabetes. Jeddah office opening in 2016 marked major milestone in partnership.
- JulpharcoreMajor pharmaceutical partnership including joint venture for Julphar Saudi Arabia manufacturing facility in King Abdullah Economic City (SAR 200 million investment). Cigalah serves as the local partner for distribution and manufacturing of generic pharmaceutical products.
- AllergancoreStrategic partnership for Allergan Saudi LLC establishment, a multi-specialty healthcare company focused on branded pharmaceuticals, devices, and biological products. Celebrated inauguration in March 2017.
- Janssen (Johnson & Johnson)coreHealthcare sector partnership for pharmaceutical product distribution across Saudi Arabia.
- Gilead SciencescoreHealthcare sector partnership for pharmaceutical product distribution.
- TakedacoreHealthcare sector partnership for pharmaceutical product distribution.
- AmgencoreHealthcare sector partnership for pharmaceutical product distribution.
- MSD (Merck & Co.)coreHealthcare sector partnership for pharmaceutical product distribution including vaccines.
- SanoficoreHealthcare sector partnership for pharmaceutical product distribution.
- Abbott LaboratoriescoreHealthcare sector partnership for pharmaceutical and diagnostic product distribution. Also partner in bio-medical sector.
- BayercoreHealthcare sector partnership for pharmaceutical product distribution.
- Mylan (Viatris)coreHealthcare sector partnership for generic pharmaceutical product distribution.
- RB (Reckitt Benckiser)coreConsumer products partnership for OTC/healthcare products including Gaviscon.
- BiopharmacoreDistribution partner for ImmunityBio ANKTIVA launch in Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer treatments.
- United Naghi GroupcoreParent organization with over 100 years of history in pharmaceutical and consumer products. Includes sister companies: Naghi Motors, Hafil Transport, Arabian Trading Supplies, Arabian Food Supplies, Yousef Naghi Electronics, Gulf Medical. Daughter companies: SAF Sector, Aghrass Medical, Zawaq Foods, Cigalah Surgical Packs Factory, Al-Qantarah Sector, Alpha Pharma.
- Buruj Cooperative InsuranceminorInvestment holding in Buruj Cooperative Insurance Company.
- Julphar Saudi ArabiacoreJoint venture manufacturing facility producing 1 billion tablets, 300 million capsules, and 30 million bottles of syrups/suspensions annually. SAR 200 million investment in King Abdullah Economic City.
- Batterjee PharmacoreInvestment and distribution partnership for Batterjee Pharma products.
- Friesland Campina Saudi ArabiacoreDistribution partnership for dairy and nutritional products.
- NutriciacoreHealthcare sector partnership for medical nutrition products including baby milk formula.
- DanonecoreHealthcare sector partnership for medical nutrition products.
- CSL BehringcoreHealthcare sector partnership for specialty pharmaceutical products.
- BioMarincoreHealthcare sector partnership for specialty pharmaceutical products.
- ActelioncoreHealthcare sector partnership for specialty pharmaceutical products.
Scale indicators10 records
Recent moves9 records
Expansion highlights5 records
Cigalah Group competitors and assessment
Company assessmentDirect peers
- Salehiya Trading Company: One of the largest pharmaceutical and healthcare distribution companies in Saudi Arabia, supplying hospitals, pharmacies and government institutions. Directly comparable to Cigalah's healthcare sector in customer base (8,000+ pharmacies), product portfolio and B2B distribution model across the Kingdom.
- AJA Pharmaceutical Industries: Saudi pharmaceutical manufacturer and distributor serving local and regional markets with branded and generic products. Operates a comparable model of pharma distribution plus light manufacturing and serves the same Saudi pharmacy and hospital customer base as Cigalah's healthcare sector.
- Al-Jazira Pharmaceuticals: Saudi-based pharmaceutical distribution company providing medicines and medical supplies to pharmacies, hospitals and healthcare institutions across the Kingdom. Closely comparable to Cigalah's core healthcare distribution activity in customer mix and product portfolio.
- Pharma International Company: Jordan-headquartered pharmaceutical manufacturer and distributor with significant operations across Saudi Arabia and the broader MENA region. Comparable to Cigalah in its dual manufacturing-plus-distribution model and Saudi-focused go-to-market.
Broad incumbents
- SPIMACO Addwaeih: Major Saudi pharmaceutical manufacturer and distributor with a broad portfolio of branded generics and consumer healthcare products. Larger and more vertically integrated than Cigalah, SPIMACO overlaps in pharma distribution to Saudi pharmacies and hospitals and competes for the same multinational manufacturing/distribution partnerships.
- Dallah Healthcare Holding: Major Saudi healthcare conglomerate operating hospitals, clinics and pharmaceutical/healthcare distribution. Larger and more diversified than Cigalah, but overlaps in healthcare distribution and serves the same institutional pharmacy and hospital customers.
Regional players
- Tabuk Pharmaceuticals: Leading Saudi pharmaceutical manufacturer with distribution across MENA. Comparable to Cigalah's healthcare distribution activities and JV manufacturing model (e.g., Julphar Saudi), though primarily a manufacturer with selective distribution; competes for the same principals and government contracts.
- Al Ittihad Drug Store: UAE-based pharmaceutical distribution company serving pharmacies and healthcare institutions primarily in the UAE market. Comparable distribution model and customer base to Cigalah's healthcare sector, but geographically focused on the Emirates rather than Saudi Arabia.
Others
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and Cigalah's joint venture partner in the SAR 200M Julphar Saudi Arabia manufacturing facility. Strategic partner rather than direct competitor, but operates in the same regional pharma value chain and serves overlapping MENA customers.
Emerging players
- Aumet: AI-first healthcare procurement platform operating across Jordan, Egypt and Saudi Arabia, in which Cigalah invested as part of a $12M Series A. Adjacent rather than directly competing, but represents the emerging digital procurement layer that could complement or disrupt traditional pharma distribution.
Market position
Strengths6 records
Weaknesses5 records
Competitive moat6 records
Key risks1 record
Key highlights1 record
Customer concentration
Cigalah Group social profiles
Digital presenceCigalah Group compliance and trust
Trust signalCompliance5 records
Cigalah Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cigalah Group leadership team
Management profileNumber of profiles
Profiles8 records
Cigalah Group subsidiaries and ownership
Company hierarchySubsidiaries11 records
Cigalah Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cigalah Group M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cigalah Group
What does Cigalah Group do?
Cigalah Group is a Saudi Arabian sales, distribution and marketing conglomerate that distributes pharmaceutical, healthcare, consumer goods, and bio-medical products from international principals to wholesale, retail, hospital and institutional channels across the Kingdom and GCC. It operates 10 consumer products distribution hubs and 5 healthcare/pharmaceutical distribution hubs, supported by a fleet of cash vans, a medical sales force, and 36,100 sqm of GDP-compliant temperature-controlled warehousing.
Is Cigalah Group a public or private company?
Cigalah Group is a private company. It is classified as family owned and is currently operating.
When was Cigalah Group founded?
Cigalah Group was founded in 1986. It employs 1,001 to 5,000 people.
Where is Cigalah Group based?
Cigalah Group is headquartered in Jeddah, Saudi Arabia, in the Middle East region.
How does Cigalah Group make money?
Four revenue lines are on record. Pharmaceutical Distribution is the primary driver. The others are consumer Products Distribution, food Manufacturing and Export and technology Transfer and Licensing.
Who are Cigalah Group's main competitors?
Direct peers on record are Salehiya Trading Company, AJA Pharmaceutical Industries, Al-Jazira Pharmaceuticals and Pharma International Company. Broad incumbents are SPIMACO Addwaeih and Dallah Healthcare Holding. Regional players are Tabuk Pharmaceuticals and Al Ittihad Drug Store. Julphar (Gulf Pharmaceutical Industries) is listed as an others. Aumet is listed as an emerging player.
Does Cigalah Group have an API?
No public API is recorded for Cigalah Group.